Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study

INTRODUCTION: This study presents the results of a real-life, multicenter, prospective, post-approval safety evaluation of Clairyg® 50 mg/mL, a 5% intravenous immunoglobulin (IVIg) liquid, in 59 children (aged < 12 years) with primary immunodeficiency diseases (PID) (n = 32) or immune thrombocyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahlaoui, Nizar, Fouyssac, Fanny, Mazingue, Françoise, Mallebranche, Coralie, Barthez-Toullec, Malika, Denti, Lamia, Ruhier, Kalaivani, André-Bonnet, Marie-Hélène, Marie-Cardine, Aude, Aladjidi, Nathalie, Stephan, Jean-Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577179/
https://www.ncbi.nlm.nih.gov/pubmed/37849499
http://dx.doi.org/10.3389/fped.2023.1260296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577179/
https://www.ncbi.nlm.nih.gov/pubmed/37849499
http://dx.doi.org/10.3389/fped.2023.1260296

Ejemplares similares